StreetInsider.com News Articles

Adial Pharmaceuticals (ADIL) Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

Tue, 13 Aug 2024 09:03:13 -0400

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced a collaboration with Boudicca Dx, LLC, a global precision medicine testing accelerator.

Under the agreement, Boudicca will support Adial in advancing its technical and regulatory strategy for the Company’s companion diagnostic genetic test, to ensure it is validated both technically and clinically per FDA guidelines as part of Adial’s regulatory strategy for its lead investigational asset, AD04, a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use

Adial Pharmaceuticals (ADIL) Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

Tue, 13 Aug 2024 09:03:13 -0400

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced a collaboration with Boudicca Dx, LLC, a global precision medicine testing accelerator.

Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

Tue, 13 Aug 2024 09:00:00 -0400

GLEN ALLEN, Va., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced a collaboration with Boudicca Dx, LLC, a global precision medicine testing accelerator.

Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

Tue, 13 Aug 2024 09:00:00 -0400

Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

Tue, 13 Aug 2024 09:00:00 -0400

Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

Tue, 13 Aug 2024 09:00:00 -0400

Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

Tue, 13 Aug 2024 09:00:00 -0400

Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

Tue, 13 Aug 2024 09:00:00 -0400

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Wed, 07 Aug 2024 09:00:00 -0400

Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04

Topline results expected during the fourth quarter

GLEN ALLEN, Va., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced that the final patient has completed the last dose in the pharmacokinetics study of AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Wed, 07 Aug 2024 09:00:00 -0400

Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04

Topline results expected during the fourth quarter

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Wed, 07 Aug 2024 09:00:00 -0400

Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04

Topline results expected during the fourth quarter

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Wed, 07 Aug 2024 09:00:00 -0400

Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04

Topline results expected during the fourth quarter

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Wed, 07 Aug 2024 09:00:00 -0400

Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04

Topline results expected during the fourth quarter

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Wed, 07 Aug 2024 09:00:00 -0400

Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04

Topline results expected during the fourth quarter

Adial Pharmaceuticals (ADIL) Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Wed, 31 Jul 2024 08:32:11 -0400

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the filing of a new patent application for AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day). The patent, assuming granted, is expected to protect Adial’s core assets through at least 2044.

Cary Claiborne, President and Chief Executive Officer of Adial commented, “As we continue to advance the AD04 program

Adial Pharmaceuticals (ADIL) Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Wed, 31 Jul 2024 08:32:11 -0400

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the filing of a new patent application for AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day). The patent, assuming granted, is expected to protect Adial’s core assets through at least 2044.

Cary Claiborne, President and Chief Executive Officer of Adial commented, “As we continue to advance the AD04 program

Adial Pharmaceuticals (ADIL) Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Wed, 31 Jul 2024 08:32:11 -0400

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the filing of a new patent application for AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day). The patent, assuming granted, is expected to protect Adial’s core assets through at least 2044.

Cary Claiborne, President and Chief Executive Officer of Adial commented, “As we continue to advance the AD04 program

Adial Pharmaceuticals (ADIL) Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Wed, 31 Jul 2024 08:32:11 -0400

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the filing of a new patent application for AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day). The patent, assuming granted, is expected to protect Adial’s core assets through at least 2044.

Cary Claiborne, President and Chief Executive Officer of Adial commented, “As we continue to advance the AD04 program

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044